Abstract Body

Background: In the U.S., 2014 CDC guidelines based on expert recommendations have for the first time recommended PrEP as one of several options for fertile HIV-uninfected female/HIV-1-infected male couples on combination antiretroviral therapy (cART) with plasma HIV RNA <50 copies/mL desiring a child. However, in other Northern countries, medically assisted procreation (MAP) is still the recommended strategy. The aim of this study was to assess residual risk of HIV transmission, cost, and cost-effectiveness (CE) of various strategies that can help fertile HIV serodiscordant couples to have a child: (i) unprotected sexual intercourse (TasP); (ii) TasP limited to fertile days (FertilD); (iii) TasP with pre-exposure prophylaxis (PrEP) (tenofovir/emtricitabine); (iv) strategy (ii) + PrEP limited to fertile days; (v) medically assisted procreation (MAP).

Methods: We used a decision model. Input variables were from the international literature: 85% probability of live births in different strategies, 0.0083%/month HIV-transmission risk (β) with unprotected vaginal intercourse, 1% HIV mother-to-child transmission rate, and 4.4% birth defect risk related to cART when mother infected at conception. FertilD and PrEP were estimated to decrease β by 80% and 67%, respectively, and by 93.4% for PrEP+FertilD (1-(1-0.80)*(1-0.67)). Tenofovir/emtricitabine monthly cost was at €540. The CE analysis was performed from the French societal perspective (2013 euros), with a 4% annual discount rate.

Results: The probability of transmission to the female partner was highest with unprotected sexual intercourse strategy and lowest for MAP, followed by PrEP during fertile period (Table). FertilD was associated with the lowest costs and dominated PrEP, which was less effective with the highest costs. PrEP+FertilD cost-effectiveness ratio was €1,130,000/life year saved (LYS) when compared with FertilD; €3,600,000/LYS for MAP when compared with PrEP+FertilD. Results were robust to multiple sensitivity analyses.

Conclusions: In fertile HIV-uninfected female/HIV-1-infected male couples with plasma HIV RNA <50 copies/mL, targeting fertile days lead to a low risk of HIV transmission. Considering PrEP during fertile period or MAP were found to decrease the risk of infections but these strategies were associated with unfavorable CE ratio.

⇥

⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥

⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥

⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥

⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥

⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥

⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥

⇥

Reproductive strategy assessed at one year for 10,000 HIV-serodiscordant couples HIV-infected women/10,000 pregnancies HIV-infected babies/10,000 pregnancies Life expectancy* (undiscounted) Life expectancy* (3% discount rate) Costs (4% discount rate) Incremental CE ratio (€/Life year saved)
FertiD 0.9 0.002 113.046 40.408 € 785.90 —
TasP (baseline) 5.4 0.014 113.030 40.404 € 786.67 Dominated
PrEP+FertilD 0.3 0.001 113.049 40.409 € 1,324.29 1,128,000
MAP 0.0 0.000 113.050 40.409 € 3,207.79 3,595,000
PrEP 1.8 0.005 113.043 40.408 € 3,836.32 Dominated

* Life expectancy of both woman and child, woman being 33 years of age (113.046 = LE woman = 44.199 + LE baby = 68.847), rounded to three decimal places.